即时分子诊断市场－全球产业规模、份额、趋势、机会及预测（依技术、应用、检测地点、最终用户、地区及竞争格局划分，2021-2031年）

全球即时分子诊断市场预计将从 2025 年的 28.8 亿美元成长到 2031 年的 54.5 亿美元，复合年增长率为 11.21%。

即时分子诊断利用自动化检测平台，在患者照护现场即可即时辨识致病遗传物质和突变。这些可携式系统无需中央检查室处理即可提供快速且准确的结果，从而加快临床决策。推动市场发展的关键因素是全球感染疾病率的上升以及医疗服务分散化的趋势，这需要便捷的检测解决方案。此外，微流体技术的不断进步提高了这些设备的运作速度和易用性，促进了它们在各种医疗机构中的应用。

然而，由于法规环境严格和合规成本高昂，该行业面临严峻挑战。向更严格的监管框架过渡给製造商带来了沉重的财务负担，抑制了创新并延缓了产品上市。例如，根据欧洲医疗技术协会（MedTech Europe）报告，到2024年，根据新的体外诊断医疗设备法规（IVDR），製造商的认证成本可能比先前的指令增加高达100%。成本的增加提高了准入门槛，并可能阻碍经济高效的诊断解决方案的广泛应用。

市场驱动因素

全球感染疾病和流行病负担日益加重，成为推动市场发展的主要因素，也因此迫切需要能够快速识别流感、呼吸道合胞病毒（RSV）和新冠病毒（COVID-19）等病原体的可靠诊断工具。随着呼吸道病毒的持续流行，医疗系统正优先考虑能够区分重迭症状并改善患者管理的多重分子检测。这项强劲需求体现在提供全面呼吸道检测组合的主要产业参与者的商业性成功。根据丹纳赫公司于2025年1月发布的2024年第四季财务报告，Cepheid公司仅在第四季呼吸道检测收入就达到了约5.5亿美元。这主要得益于市场对其四联检测套组的强劲需求，凸显了市场对分子照护现场解决方案在季节性疫情管理中的依赖。

同时，随着医疗分散化和床边检测的兴起，先进的诊断技术正从中心检查室转移到诊所和急诊中心，整个产业也因此经历变革。紧凑型平台能够在非传统环境下提供检查室级的检测结果，显着缩短治疗时间，从而推动了这一转变。製造商正积极扩大装机量，以满足这种更贴近患者的检测需求。根据生物梅里埃公司于2025年3月发布的2024年财务报告，SPOTFIRE照护现场系统的年销售额预计将达到约9,500万欧元，装置量将达到3,000台。儘管取得了这些进展，但全球范围内的医疗服务可近性仍有显着差异。 2024年10月，世界卫生组织（世卫组织）指出，仅48%的新确诊结核病病例使用世卫组织推荐的快速分子诊断作为初始检测方法，这凸显了巨大的未满足需求，并将推动未来的市场扩张。

市场挑战

严格的法规环境和相关的合规成本是该领域发展的一大障碍，严重限制了市场成长势头。随着监管机构为确保设备安全性和性能而实施更严格的标准，製造商被迫将大量资源从研发转移到应对复杂的核准流程。这种资金和技术专长的转移减缓了创新步伐，阻碍了突破性诊断平台有效率地进入商业化阶段。所需的大量文件和临床证据延长了研发週期，延缓了关键即时检测解决方案的普及应用。

这些监管压力正在积极重塑全球市场策略，导致製造商对认证时间难以预测的市场犹豫不决或选择退出。过度关注合规性使得曾经的医疗科技创新中心地区吸引力下降。根据欧洲医疗技术协会（MedTech Europe）预测，到2024年，与新法规结构相关的挑战将导致选择欧盟作为首发产品优先市场的领先诊断製造商数量下降40%。这一趋势表明，监管负担正在直接阻碍分子诊断技术的广泛应用和普及。

市场趋势

基于 CRISPR 的诊断技术的出现正在革新市场，它无需复杂的热感热处理，即可实现与传统 PCR 相当的高灵敏度无仪器分子检测。该技术利用 Cas 酶直接从样本中识别特定基因标靶，显着降低了照护现场)的设备复杂性和製造成本。这项创新技术的商业性扩充性正在推动关键的策略性收购，旨在部署用于分散式筛检的下一代检测方法。根据 OraSure Technologies 公司关于其于 2024 年 12 月收购 Sherlock Biosciences 的新闻稿，该公司估计仅 Sherlock 基于 CRISPR 的披衣菌感染和淋病自检检测套组的潜在市场规模就超过 15 亿美元，凸显了这些先进的基因编辑诊断技术蕴藏的巨大经济机会。

同时，消费级和家用分子检测套组的普及正在彻底改变患者的就医方式，使个人能够在家中进行检查室层级的检测。製造商正迅速获得监管部门核准，推出用于诊断性行为感染传染病和呼吸道疾病的商业平台，从而绕过传统的临床瓶颈和医生转诊。这一趋势吸引了大量投资，用于扩大主导消费者的诊断产品的生产和分销网络，以满足不断增长的需求。根据Ctech 2025年6月的一篇报导，Visby Medical筹集了约5500万美元，以加速其获得FDA批准的家用性健康检测产品的商业推广，这凸显了该行业正迅速向以用户为中心的诊断模式转变。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球即时分子诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（基于PCR、基于基因定序、基于杂合反应、基于微阵列）
  • 依应用领域（感染疾病、肿瘤学、血液学、产前检测、内分泌学等）
  • 按测试地点（OTC、POC）
  • 按最终使用者（分散式检查实验室、医院、居家医疗、辅助生活设施、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美即时分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲即时分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区即时分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲即时分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲即时分子诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球即时分子诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Siemens Healthineers AG
• Quidel Corporation
• F. Hoffman-La Roche Ltd.
• Danaher Corporation
• Beckton & Dickinson Company
• Trinity Biotech plc
• Thermo Fisher Scientific Inc
• bioMerieux SA
• DiaSorin SpA
• AccuBioTech Co., Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Point-Of-Care Molecular Diagnostics Market is projected to experience significant growth, rising from a valuation of USD 2.88 Billion in 2025 to USD 5.45 Billion by 2031, reflecting a CAGR of 11.21%. Point-of-care molecular diagnostics utilize automated testing platforms to identify pathogenic genetic material or mutations immediately at the site of patient care. These portable systems provide rapid and accurate results without the need for centralized laboratory processing, facilitating prompt clinical decision-making. The market is largely driven by the rising global prevalence of infectious diseases and a shift toward decentralized healthcare that demands accessible testing solutions. Additionally, ongoing advancements in microfluidics have improved the speed and usability of these devices, supporting their adoption across various medical settings.

However, the industry faces substantial challenges due to strict regulatory environments and high compliance costs. The move toward more rigorous frameworks has placed significant financial burdens on manufacturers, which threatens to stifle innovation and delay product launches. For example, MedTech Europe reported that in 2024, certification costs for manufacturers under the new In Vitro Diagnostic Regulation rose by up to 100 percent compared to previous directives. This increase in expenses establishes a high barrier to entry and may hinder the widespread expansion of cost-effective diagnostic solutions.

Market Driver

The escalating global burden of infectious diseases and pandemics serves as a primary catalyst for the market, creating a critical need for robust diagnostic tools capable of rapidly identifying pathogens such as influenza, RSV, and COVID-19. As respiratory viruses continue to co-circulate, healthcare systems are prioritizing multiplex molecular assays that can differentiate between overlapping symptoms to improve patient management. This strong demand is reflected in the commercial success of major industry players offering comprehensive respiratory panels. According to Danaher Corporation's Q4 2024 earnings results released in January 2025, Cepheid's respiratory testing revenue hit approximately $550 million in the fourth quarter alone, driven by high volumes of their four-in-one test, underscoring the market's reliance on molecular point-of-care solutions for managing seasonal outbreaks.

Simultaneously, the growing shift toward decentralized healthcare and near-patient testing is transforming the industry by relocating advanced diagnostics from central labs to clinics and urgent care centers. This transition is supported by compact platforms that deliver lab-quality results in non-traditional settings, significantly accelerating time-to-treatment. Manufacturers are aggressively expanding their installed bases to meet this demand for accessible testing closer to the patient. According to bioMerieux's 2024 financial results from March 2025, sales of the SPOTFIRE point-of-care system reached nearly €95 million for the year, with an installed base of 3,000 units. despite this progress, significant gaps remain in global access; the World Health Organization noted in October 2024 that only 48 percent of newly diagnosed tuberculosis cases were tested using a WHO-recommended rapid molecular diagnostic as the initial test, highlighting the immense unmet need driving future market expansion.

Market Challenge

The sector encounters major obstacles regarding stringent regulatory environments and associated compliance costs, which act as a significant brake on market momentum. As regulatory bodies enforce more rigorous standards to ensure device safety and performance, manufacturers are forced to reallocate critical resources from research and development toward navigating complex approval processes. This diversion of capital and technical expertise slows the pace of innovation, preventing potentially breakthrough diagnostic platforms from reaching the commercial stage efficiently. The sheer volume of documentation and clinical evidence required creates prolonged development cycles, delaying the availability of essential point-of-care solutions.

These regulatory pressures are actively reshaping global market strategies, causing manufacturers to hesitate or withdraw from markets with unpredictable certification timelines. The intense focus on compliance reduces the attractiveness of regions that were once hubs for medical technology innovation. According to MedTech Europe, in 2024, the percentage of large diagnostic manufacturers selecting the European Union as their priority region for first product launches declined by 40% due to the challenges associated with the new regulatory framework. This trend demonstrates how regulatory burdens are directly impeding the widespread expansion and accessibility of molecular diagnostic technologies.

Market Trends

The emergence of CRISPR-based diagnostic technologies is revolutionizing the market by enabling highly sensitive, instrument-free molecular detection that rivals traditional PCR without requiring complex thermal cycling. This technology utilizes Cas enzymes to identify specific genetic targets directly from samples, significantly reducing device complexity and manufacturing costs for point-of-care settings. The commercial scalability of this innovation is driving major strategic acquisitions aimed at deploying next-generation assays for decentralized screening. According to OraSure Technologies in a December 2024 press release regarding the acquisition of Sherlock Biosciences, the company estimates that the total addressable market for Sherlock's CRISPR-based Chlamydia and Gonorrhea self-test alone represents more than $1.5 billion, underscoring the immense financial opportunity in these advanced gene-editing diagnostics.

Simultaneously, the expansion of direct-to-consumer and home-use molecular testing kits is fundamentally altering patient access by allowing individuals to perform lab-quality assays in their own homes. Manufacturers are increasingly securing regulatory authorizations for over-the-counter platforms that diagnose sexual health and respiratory conditions, thereby bypassing traditional clinical bottlenecks and physician referrals. This trend is attracting substantial investment capital aimed at scaling manufacturing and distribution networks for consumer-initiated diagnostics to meet rising public demand. According to a Ctech article from June 2025, Visby Medical raised approximately $55 million specifically to accelerate the commercial reach of its FDA-cleared at-home sexual health test, highlighting the sector's rapid pivot toward user-centric diagnostic models.

Key Market Players

• Siemens Healthineers AG
• Quidel Corporation
• F. Hoffman-La Roche Ltd.
• Danaher Corporation
• Beckton & Dickinson Company
• Trinity Biotech plc
• Thermo Fisher Scientific Inc
• bioMerieux S.A.
• DiaSorin S.p.A
• AccuBioTech Co., Ltd.

Report Scope

In this report, the Global Point-Of-Care Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-Of-Care Molecular Diagnostics Market, By Technology

• PCR-based
• Genetic Sequencing-based
• Hybridization-based
• Microarray-based

Point-Of-Care Molecular Diagnostics Market, By Application

• Infectious Diseases
• Oncology
• Hematology
• Prenatal Testing
• Endocrinology
• Other

Point-Of-Care Molecular Diagnostics Market, By Test Location

• OTC
• POC

Point-Of-Care Molecular Diagnostics Market, By End User

• Decentralized Labs
• Hospitals
• Home-care
• Assisted Living Healthcare Facilities
• Others

Point-Of-Care Molecular Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-Of-Care Molecular Diagnostics Market.

Available Customizations:

Global Point-Of-Care Molecular Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point-Of-Care Molecular Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based)
  • 5.2.2. By Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, Other)
  • 5.2.3. By Test Location (OTC, POC)
  • 5.2.4. By End User (Decentralized Labs, Hospitals, Home-care, Assisted Living Healthcare Facilities, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Point-Of-Care Molecular Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Test Location
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Point-Of-Care Molecular Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Test Location
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Point-Of-Care Molecular Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Test Location
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Point-Of-Care Molecular Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Test Location
      • 6.3.3.2.4. By End User

7. Europe Point-Of-Care Molecular Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Test Location
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Test Location
      • 7.3.1.2.4. By End User
  • 7.3.2. France Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Test Location
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Test Location
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Test Location
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Point-Of-Care Molecular Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Test Location
      • 7.3.5.2.4. By End User

8. Asia Pacific Point-Of-Care Molecular Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Test Location
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Test Location
      • 8.3.1.2.4. By End User
  • 8.3.2. India Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Test Location
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Test Location
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Test Location
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Point-Of-Care Molecular Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Test Location
      • 8.3.5.2.4. By End User

9. Middle East & Africa Point-Of-Care Molecular Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Test Location
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Point-Of-Care Molecular Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Test Location
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Point-Of-Care Molecular Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Test Location
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Point-Of-Care Molecular Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Test Location
      • 9.3.3.2.4. By End User

10. South America Point-Of-Care Molecular Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Test Location
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Point-Of-Care Molecular Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Test Location
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Point-Of-Care Molecular Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Test Location
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Point-Of-Care Molecular Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Test Location
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Point-Of-Care Molecular Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Siemens Healthineers AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Quidel Corporation
• 15.3. F. Hoffman-La Roche Ltd.
• 15.4. Danaher Corporation
• 15.5. Beckton & Dickinson Company
• 15.6. Trinity Biotech plc
• 15.7. Thermo Fisher Scientific Inc
• 15.8. bioMerieux S.A.
• 15.9. DiaSorin S.p.A
• 15.10. AccuBioTech Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer